Orthocell, Antisense bolster IP portfolios

Orthocell (ASX:OTI) and Antisense Therapeutics (ASX:ANP) have both secured additions to their respective intellectual property portfolios.

Orthocell has been granted an Australian patent related to its tendon-regeneration technology, Ortho-ATI.

The patent covers the use of biological materials to repair damaged tendons, via the preparation of bioscaffolds and tendon stem cells to treat rotator cuff tears.

Specifically, it relates to Orthocell’s method of cultivating and growing patient’s tendon cells, seeding them into a scaffold and implanting them close to the tear.

Orthocell already has process patents covering Ortho-ATI in New Zealand, Singapore and China.

Antisense Therapeutics separately revealed it has been issued a notice of allowance from the European Patent Office covering its ATL1102 compound in relapsing-remitting multiple sclerosis (RRMS).

The patent will cover “Methods for treating multiple sclerosis using antisense oligonucleotides”. It extends Antisense’s protection for ATL1102 in the condition through to 2029, with the potential for a further five-year extension.

Antisense will be granted the patent in the next few months. The company also has two US and one Australian patent protecting ATL1102 in RRMS, and has applications pending in Japan and Canada.

Antisense Therapeutics (ASX:ANP) shares were trading 3.57% higher at $0.145 as of around 1.30 pm on Tuesday, while Orthocell (ASX:OTI) shares were unchanged at $0.08.